Results 261 to 270 of about 174,708,283 (296)
Some of the next articles are maybe not open access.
Mammalian target of rapamycin: A new target in prostate cancer
Urologic Oncology: Seminars and Original Investigations, 2010Molecular targets in prostate cancer are continually being explored, especially in the poor-prognosis androgen-independent phase of the disease, for which there are currently few therapeutic options. One such target is the mammalian target of rapamycin (mTOR) protein.
Jaskarn S, Rai +2 more
openaire +2 more sources
Inhibitors of the Mammalian Target of Rapamycin and Transplant Tolerance
Transplantation, 2009Certainly, achieving and maintaining donor-specific hyporesposiveness is a main challenge nowadays in organ transplantation to improve long-term graft survival. Immunosuppression seems to be mandatory in the majority of renal transplant patients. However, some specific drugs have shown to have interesting immunomodulatory effects, regardless of their ...
Oriol, Bestard +2 more
openaire +2 more sources
Common toxicities of mammalian target of rapamycin inhibitors
Targeted Oncology, 2011The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities.
Scott A, Soefje +2 more
openaire +2 more sources
[mTOR, the mammalian target of rapamycin].
Medecine sciences : M/S, 2011The discovery of rapamycin from a soil sample on Easter Island in the mid 60's marked the beginning of an exciting field of research in cell biology and medicine. While it was first used as an antifungal and as an immunosuppressive drug, more recent studies confirmed rapamycin's antiproliferative properties over a variety of solid tumors.
Louis-André, Julien, Philippe P, Roux
openaire +1 more source
Mammalian Target of Rapamycin (mTOR)
2005The mammalian target of rapamycin (mTOR) is a giant serine/threonine protein kinase that plays a crucial role in a nutrient-sensitive signaling pathway that regulates cell growth and proliferation. The activity of mTOR is controlled by amino acids (especially by leucine, one of the branched-chain amino acids), in addition to growth factors and overall ...
openaire +1 more source
Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors
Transplantation Reviews, 2008Mammalian target of rapamycin (mTOR) integrates nutrient and hormonal signals involved in cell growth. Development of mTOR inhibitor drugs as therapeutic agents for major human diseases such as obesity, diabetes, atherosclerosis, or cancer will experience an important increase in the next years. The incidence of these diseases is particularly increased
openaire +2 more sources
Clinical development of mammalian target of rapamycin inhibitors
Hematology/Oncology Clinics of North America, 2002Rapamycin and CCI-779 have significant in vitro and in vivo anti-proliferative activity against a broad range of human tumor cell lines, justifying the clinical evaluation of this class of agent in cancer patients. Preliminary results from phase I studies of CCI-779 suggest that the agent is well tolerated and has anti-tumor activity.
openaire +2 more sources
Mammalian target of rapamycin and tuberous sclerosis complex
Journal of Dermatological Science, 2015Mammalian target of rapamycin (mTOR) is an evolutionarily conserved serine/threonine kinase that is a member of the phosphoinositide 3-kinase (PI3K)-related kinase (PIKK) family. mTOR forms two distinct complexes, mTORC1 and mTORC2. mTORC1 has emerged as a central regulator of cellular metabolism, cell proliferation, cellular differentiation, autophagy
openaire +2 more sources
Mammalian Target of Rapamycin as a Target in Hematological Malignancies
Current Problems in Cancer, 2008Isam A, Abdel-Karim, Francis J, Giles
openaire +2 more sources